Roger Lo, M.D., Ph.D.

A Short Biography:

The Roger S. Lo Laboratory is focused on melanoma research in three thematic areas: 1. Discovering somatically mutated genes in melanoma using exon capture and next-generation sequencing and studying these genes in the pathogenesis of melanoma. 2. Dissecting oncogene co-dependent survival networks in melanoma using V600EB-RAF as a prototypic melanoma oncogene and siRNA library as a discovery tool. 3. Understand the mechanisms of primary and acquired resistance to targeted therapies (including B-RAF inhibitors) using integrated genomic technologies. It is affiliated with the Department of Medicine/Division of Dermatology and the Jonsson Comprehensive Cancer Center (Tumor Cell Biology Program)

Work Titles
UCLA Director, Melanoma Clinic in Dermatology Director, Dermatology STAR Residency Program Professor, Medicine Associate Chief and Professor, Dermatology Professor, Molecular & Medical Pharmacology Member, Genetics & Genomics GPB Home Area Member, Immunity, Microbes & Molecular Pathogenesis GPB Home Area Member, JCCC Signal Transduction and Therapeutics Program Area Member, Molecular Pharmacology GPB Home Area
M.D., Cornell University Medical College, 1998 - 2002
Ph.D., Sloan-Kettering Tri-Institutional MD-PhD Program, 2002
2002 - 2003 St. Vincent's Hospital and Medical Center
2003 - 2006 UCLA School of Medicine
2007 American Board of Dermatology

Contact Information:

Work Phone Number:


Mailing Address:

Practice Location
STE 450, 200 Medical Plaza
Los Angeles, CA 90095

Detailed Biography:

Dr. Roger Lo is Professor of Medicine/Dermatology, Associate Chief of Dermatology and Director of the Dermatology STAR Program at UCLA’s David Geffen School of Medicine.  He earned his BS in Biology with Honors and Distinction in 1994 from Stanford University and his MD and PhD degrees from the Tri-institutional (Weill Cornell, Memorial Sloan-Kettering, and Rockefeller) MD-PhD Program in 2002. After completing residency and postdoctoral work at UCLA, he joined the faculty in 2008. Work from his group has been recognized for providing the major scientific rationale toward the use of inhibitors of BRAF and MEK in combination to effectively treat melanoma – a therapeutic approach that is now globally considered the standard of care. Studies from his group have provided rationale to additional clinical trials and foundational knowledge on the roles of tumor heterogeneity, non-genomic processes and the tumor microenvironment in determining clinical responses to mutation-targeted and immunotherapies. His work has been published in Nature, New England Journal of Medicine, Cancer Discovery, Cancer Cell, and Cell. Dr. Lo was elected to the American Society for Clinical Investigation in 2012 and American Dermatological Association in 2015. In 2013 Dr. Lo received the 33rd Annual Award for Outstanding Achievement in Cancer Research from the American Association for Cancer Research (AACR). In 2017, Dr. Lo received the inaugural AACR-Waun Ki Hong Award for Outstanding Achievement in Cancer Research. Dr. Lo has received the Innovative Research Grant from Stand Up to Cancer and the Milstein Innovation Award for the American Skin Association. He currently serves on the Editorial Board of Cancer Discovery .


A selected list of publications:

Huang Lu, Malu Shruti, McKenzie Jodi A, Andrews Miles C, Talukder Amjad H, Tieu Trang, Karpinets Tatiana, Haymaker Cara, Forget Marie-Andrée, Williams Leila J, Wang Zhe, Mbofung Rina M, Wang Zhi-Qiang, Davis Richard Eric, Lo Roger S, Wargo Jennifer A, Davies Michael A, Bernatchez Chantale, Heffernan Timothy, Amaria Rodabe N, Korkut Anil, Peng Weiyi, Roszik Jason, Lizée Gregory, Woodman Scott E, Hwu Patrick   The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression Clinical cancer research : an official journal of the American Association for Cancer Research, 2018; 24(14): 3366-3376.
Huang Dian, Leslie Kevin A, Guest Daniel, Yeshcheulova Olga, Roy Irena J, Piva Marco, Moriceau Gatien, Zangle Thomas A, Lo Roger S, Teitell Michael A, Reed Jason   High-Speed Live-Cell Interferometry: A New Method for Quantifying Tumor Drug Resistance and Heterogeneity Analytical chemistry, 2018; 90(5): 3299-3306.
Hong Aayoung, Moriceau Gatien, Sun Lu, Lomeli Shirley, Piva Marco, Damoiseaux Robert, Holmen Sheri L, Sharpless Norman E, Hugo Willy, Lo Roger S   Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma Cancer discovery, 2018; 8(1): 74-93.
Song Chunying, Piva Marco, Sun Lu, Hong Aayoung, Moriceau Gatien, Kong Xiangju, Zhang Hong, Lomeli Shirley, Qian Jin, Yu Clarissa C, Damoiseaux Robert, Kelley Mark C, Dahlman Kimberley B, Scumpia Philip O, Sosman Jeffrey A, Johnson Douglas B, Ribas Antoni, Hugo Willy, Lo Roger S   Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation Cancer discovery, 2017; 7(11): 1248-1265.
Shin Daniel Sanghoon, Zaretsky Jesse M, Escuin-Ordinas Helena, Garcia-Diaz Angel, Hu-Lieskovan Siwen, Kalbasi Anusha, Grasso Catherine S, Hugo Willy, Sandoval Salemiz, Torrejon Davis Y, Palaskas Nicolaos, Rodriguez Gabriel Abril, Parisi Giulia, Azhdam Ariel, Chmielowski Bartosz, Cherry Grace, Seja Elizabeth, Berent-Maoz Beata, Shintaku I Peter, Le Dung T, Pardoll Drew M, Diaz Luis A, Tumeh Paul C, Graeber Thomas G, Lo Roger S, Comin-Anduix Begoña, Ribas Antoni   Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations Cancer discovery, 2017; 7(2): 188-201.
Hugo Willy, Zaretsky Jesse M, Sun Lu, Song Chunying, Moreno Blanca Homet, Hu-Lieskovan Siwen, Berent-Maoz Beata, Pang Jia, Chmielowski Bartosz, Cherry Grace, Seja Elizabeth, Lomeli Shirley, Kong Xiangju, Kelley Mark C, Sosman Jeffrey A, Johnson Douglas B, Ribas Antoni, Lo Roger S   Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma Cell, 2017; 168(3): 542.
Zaretsky Jesse M, Garcia-Diaz Angel, Shin Daniel S, Escuin-Ordinas Helena, Hugo Willy, Hu-Lieskovan Siwen, Torrejon Davis Y, Abril-Rodriguez Gabriel, Sandoval Salemiz, Barthly Lucas, Saco Justin, Homet Moreno Blanca, Mezzadra Riccardo, Chmielowski Bartosz, Ruchalski Kathleen, Shintaku I Peter, Sanchez Phillip J, Puig-Saus Cristina, Cherry Grace, Seja Elizabeth, Kong Xiangju, Pang Jia, Berent-Maoz Beata, Comin-Anduix Begoña, Graeber Thomas G, Tumeh Paul C, Schumacher Ton N M, Lo Roger S, Ribas Antoni   Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma The New England journal of medicine, 2016; 375(9): 819-29.
Hugo Willy, Zaretsky Jesse M, Sun Lu, Song Chunying, Moreno Blanca Homet, Hu-Lieskovan Siwen, Berent-Maoz Beata, Pang Jia, Chmielowski Bartosz, Cherry Grace, Seja Elizabeth, Lomeli Shirley, Kong Xiangju, Kelley Mark C, Sosman Jeffrey A, Johnson Douglas B, Ribas Antoni, Lo Roger S   Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma Cell, 2016; 165(1): 35-44.
Hugo Willy, Shi Hubing, Sun Lu, Piva Marco, Song Chunying, Kong Xiangju, Moriceau Gatien, Hong Aayoung, Dahlman Kimberly B, Johnson Douglas B, Sosman Jeffrey A, Ribas Antoni, Lo Roger S   Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance Cell, 2015; 162(6): 1271-85.
Moriceau Gatien, Hugo Willy, Hong Aayoung, Shi Hubing, Kong Xiangju, Yu Clarissa C, Koya Richard C, Samatar Ahmed A, Khanlou Negar, Braun Jonathan, Ruchalski Kathleen, Seifert Heike, Larkin James, Dahlman Kimberly B, Johnson Douglas B, Algazi Alain, Sosman Jeffrey A, Ribas Antoni, Lo Roger S   Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction Cancer cell, 2015; 27(2): 240-56.
Shi Hubing, Hugo Willy, Kong Xiangju, Hong Aayoung, Koya Richard C, Moriceau Gatien, Chodon Thinle, Guo Rongqing, Johnson Douglas B, Dahlman Kimberly B, Kelley Mark C, Kefford Richard F, Chmielowski Bartosz, Glaspy John A, Sosman Jeffrey A, van Baren Nicolas, Long Georgina V, Ribas Antoni, Lo Roger S   Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy Cancer discovery, 2014; 4(1): 80-93.
Lo Roger S   Melanoma prognostics and personalized therapeutics at a crossroad The Journal of investigative dermatology, 2013; 133(2): 292-5.
Viros Amaya, Hayward Robert, Martin Matthew, Yashar Sharona, Yu Clarissa C, Sanchez-Laorden Berta, Zambon Alfonso, Niculescu-Duvaz Dan, Springer Caroline, Lo Roger S, Marais Richard   Topical 5-Fluorouracil Elicits Regressions of BRAF Inhibitor-Induced Cutaneous Squamous Cell Carcinoma The Journal of investigative dermatology, 2013; 133(1): 274-6.
Wilmott James S, Tembe Varsha, Howle Julie R, Sharma Raghwa, Thompson John F, Rizos Helen, Lo Roger S, Kefford Richard F, Scolyer Richard A, Long Georgina V   Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine Molecular cancer therapeutics, 2012; 11(12): 2704-8.
Krauthammer Michael, Kong Yong, Ha Byung Hak, Evans Perry, Bacchiocchi Antonella, McCusker James P, Cheng Elaine, Davis Matthew J, Goh Gerald, Choi Murim, Ariyan Stephan, Narayan Deepak, Dutton-Regester Ken, Capatana Ana, Holman Edna C, Bosenberg Marcus, Sznol Mario, Kluger Harriet M, Brash Douglas E, Stern David F, Materin Miguel A, Lo Roger S, Mane Shrikant, Ma Shuangge, Kidd Kenneth K, Hayward Nicholas K, Lifton Richard P, Schlessinger Joseph, Boggon Titus J, Halaban Ruth   Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma Nature genetics, 2012; 44(9): 1006-14.
Graham Nicholas A, Tahmasian Martik, Kohli Bitika, Komisopoulou Evangelia, Zhu Maggie, Vivanco Igor, Teitell Michael A, Wu Hong, Ribas Antoni, Lo Roger S, Mellinghoff Ingo K, Mischel Paul S, Graeber Thomas G   Glucose deprivation activates a metabolic and signaling amplification loop leading to cell death Molecular systems biology, 2012; 8(7408): 589.
Gembarska Agnieszka, Luciani Flavie, Fedele Clare, Russell Elisabeth A, Dewaele Michael, Villar Stéphanie, Zwolinska Aleksandra, Haupt Sue, de Lange Job, Yip Dana, Goydos James, Haigh Jody J, Haupt Ygal, Larue Lionel, Jochemsen Aart, Shi Hubing, Moriceau Gatien, Lo Roger S, Ghanem Ghanem, Shackleton Mark, Bernal Federico, Marine Jean-Christophe   MDM4 is a key therapeutic target in cutaneous melanoma Nature medicine, 2012; 487(7408): .
Straussman Ravid, Morikawa Teppei, Shee Kevin, Barzily-Rokni Michal, Qian Zhi Rong, Du Jinyan, Davis Ashli, Mongare Margaret M, Gould Joshua, Frederick Dennie T, Cooper Zachary A, Chapman Paul B, Solit David B, Ribas Antoni, Lo Roger S, Flaherty Keith T, Ogino Shuji, Wargo Jennifer A, Golub Todd R   Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion Nature, 2012; 487(7408): 500-4.
Lo Roger S   Receptor tyrosine kinases in cancer escape from BRAF inhibitors Cell research, 2012; 22(6): 945-7.
Shi Hubing, Moriceau Gatien, Kong Xiangju, Lee Mi-Kyung, Lee Hane, Koya Richard C, Ng Charles, Chodon Thinle, Scolyer Richard A, Dahlman Kimberly B, Sosman Jeffrey A, Kefford Richard F, Long Georgina V, Nelson Stanley F, Ribas Antoni, Lo Roger S   Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance Nature communications, 2012; 3(9): 724.
Shi Hubing, Moriceau Gatien, Kong Xiangju, Koya Richard C, Nazarian Ramin, Pupo Gulietta M, Bacchiocchi Antonella, Dahlman Kimberly B, Chmielowski Bartosz, Sosman Jeffrey A, Halaban Ruth, Kefford Richard F, Long Georgina V, Ribas Antoni, Lo Roger S   Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors Cancer discovery, 2012; 2(5): 414-24.
Paraiso Kim H T, Haarberg H Eirik, Wood Elizabeth, Rebecca Vito W, Chen Y Ann, Xiang Yun, Ribas Antoni, Lo Roger S, Weber Jeffrey S, Sondak Vernon K, John Jobin K, Sarnaik Amod A, Koomen John M, Smalley Keiran S M   The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms Clinical cancer research : an official journal of the American Association for Cancer Research, 2012; 18(9): 2502-14.
Lo Roger S   Combinatorial therapies to overcome B-RAF inhibitor resistance in melanomas Pharmacogenomics, 2012; 13(2): 125-8.
Su Fei, Viros Amaya, Milagre Carla, Trunzer Kerstin, Bollag Gideon, Spleiss Olivia, Reis-Filho Jorge S, Kong Xiangju, Koya Richard C, Flaherty Keith T, Chapman Paul B, Kim Min Jung, Hayward Robert, Martin Matthew, Yang Hong, Wang Qiongqing, Hilton Holly, Hang Julie S, Noe Johannes, Lambros Maryou, Geyer Felipe, Dhomen Nathalie, Niculescu-Duvaz Ion, Zambon Alfonso, Niculescu-Duvaz Dan, Preece Natasha, Robert Lídia, Otte Nicholas J, Mok Stephen, Kee Damien, Ma Yan, Zhang Chao, Habets Gaston, Burton Elizabeth A, Wong Bernice, Nguyen Hoa, Kockx Mark, Andries Luc, Lestini Brian, Nolop Keith B, Lee Richard J, Joe Andrew K, Troy James L, Gonzalez Rene, Hutson Thomas E, Puzanov Igor, Chmielowski Bartosz, Springer Caroline J, McArthur Grant A, Sosman Jeffrey A, Lo Roger S, Ribas Antoni, Marais Richard   RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors The New England journal of medicine, 2012; 366(3): 207-15.
Poulikakos Poulikos I, Persaud Yogindra, Janakiraman Manickam, Kong Xiangju, Ng Charles, Moriceau Gatien, Shi Hubing, Atefi Mohammad, Titz Bjoern, Gabay May Tal, Salton Maayan, Dahlman Kimberly B, Tadi Madhavi, Wargo Jennifer A, Flaherty Keith T, Kelley Mark C, Misteli Tom, Chapman Paul B, Sosman Jeffrey A, Graeber Thomas G, Ribas Antoni, Lo Roger S, Rosen Neal, Solit David B   RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) Nature, 2011; 480(7377): 387-90.
Niehr Franziska, von Euw Erika, Attar Narsis, Guo Deliang, Matsunaga Doug, Sazegar Hooman, Ng Charles, Glaspy John A, Recio Juan A, Lo Roger S, Mischel Paul S, Comin-Anduix Begonya, Ribas Antoni   Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations Journal of translational medicine, 2011; 9(15): 76.
Shi Hubing, Kong Xiangju, Ribas Antoni, Lo Roger S   Combinatorial treatments that overcome PDGFR?-driven resistance of melanoma cells to V600EB-RAF inhibition Cancer research, 2011; 71(15): 5067-74.
Atefi Mohammad, von Euw Erika, Attar Narsis, Ng Charles, Chu Connie, Guo Deliang, Nazarian Ramin, Chmielowski Bartosz, Glaspy John A, Comin-Anduix Begonya, Mischel Paul S, Lo Roger S, Ribas Antoni   Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway PloS one, 2011; 6(12): e28973.
Søndergaard Jonas N, Nazarian Ramin, Wang Qi, Guo Deliang, Hsueh Teli, Mok Stephen, Sazegar Hooman, MacConaill Laura E, Barretina Jordi G, Kehoe Sarah M, Attar Narsis, von Euw Erika, Zuckerman Jonathan E, Chmielowski Bartosz, Comin-Anduix Begoña, Koya Richard C, Mischel Paul S, Lo Roger S, Ribas Antoni   Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032 Journal of translational medicine, 2010; 8(7326): 39.
Nazarian Ramin, Shi Hubing, Wang Qi, Kong Xiangju, Koya Richard C, Lee Hane, Chen Zugen, Lee Mi-Kyung, Attar Narsis, Sazegar Hooman, Chodon Thinle, Nelson Stanley F, McArthur Grant, Sosman Jeffrey A, Ribas Antoni, Lo Roger S   Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation Nature, 2010; 468(7326): 973-7.
Lo Roger S, Witte Owen N   Transforming growth factor-beta activation promotes genetic context-dependent invasion of immortalized melanocytes Cancer research, 2008; 68(11): 4248-57.

Does this profile need updating? Contact Us